June 1, 2026 Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
May 29, 2026 Canada advances priorities on artificial intelligence, quantum technologies and digital innovation at the 2026 G7 Digital Ministers’ Meeting
February 22, 2026 Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
